Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies
| Autor: | Anne Cecile Zoung-Kany Bisseck, Jerome Ateudjieu, Blaise Genton, Beat Stoll, Ayok Maureen Tembei |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pediatrics
medicine.medical_specialty 030231 tropical medicine Immunology Meningococcal Vaccines Neisseria meningitidis 03 medical and health sciences 0302 clinical medicine medicine Immunology and Allergy 030212 general & internal medicine Pharmacology Vaccines Conjugate Immunization Programs business.industry Vaccination medicine.disease Clinical trial Safety profile Vaccination Campaigns Meningococcal conjugate vaccine business Meningitis MenAfriVac Research Paper |
| Zdroj: | Hum Vaccin Immunother Human Vaccines & Immunotherapeutics, vol. 16, no. 6, pp. 1245-1259 |
| ISSN: | 2164-554X 2164-5515 |
| Popis: | The study aimed to assess the capacity of AEFI surveillance during vaccination campaigns with the new conjugate meningitis vaccine (MenAfrivac). A systematic review of studies on MenAfrivac™ published in English during 2001-2016 was done.AEFIs incidence (I) was estimated and compared between MenAfrivac™ clinical trials and immunization campaigns using incidence difference (Id). Nine studies were included with an overall local AEFI I of 11,496/100,000 doses administered per week in clinical trials and 0.72/100,000 doses in immunization campaigns. An Id of 11,497.92 [11,497.91-11,497.93] and 17,243.20 [17,241.80-17,245.90] per 100,000 doses administered per week for overall local and systemic AEFI, respectively, were observed with highest from clinical trials. The incidence of AEFIs after MenAfrivac™ vaccination was far lower in campaigns than in clinical trial studies. Current capacity of AEFI surveillance during vaccination campaigns requires extensive re-assessment of its structure and capacity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|